Peripheral Neuropathy: Padcev injection can cause peripheral neuropathy, which may manifest as sensory or motor neuropathy. Patients should be monitored for symptoms such as numbness, tingling, or weakness in the extremities, and dose adjustments may be necessary if neuropathy occurs.
Hyperglycemia: Treatment with this medicine may lead to hyperglycemia. Blood glucose levels should be monitored regularly during treatment, and appropriate management strategies, such as antidiabetic medications or insulin, should be initiated as needed.
Ocular Disorders: this treatment may cause ocular disorders, including keratitis, which can lead to vision loss or blindness. Patients should report any changes in vision or eye discomfort to their healthcare provider promptly.
Skin Reactions: Dermatologic reactions, such as rash or pruritus, may occur with this therapeutic drug. Patients should be monitored for skin changes, and supportive care measures should be initiated as necessary.
Infusion-Related Reactions: Infusion-related reactions, including fever, chills, or hypotension, may occur during or after Padcev 20 mg or 30 mg administration. Patients should be closely monitored during infusion, and appropriate supportive care should be provided.
Embryo-Fetal Toxicity: This medicine can cause fetal harm when administered to pregnant women. Pregnancy should be avoided during treatment, and effective contraception should be used in women of childbearing potential
Interstitial Lung Disease (ILD): ILD, including pneumonitis, can occur with Padcev treatment. Patients should be monitored for respiratory symptoms, and treatment should be discontinued if ILD is suspected.
Hepatotoxicity: This drug may cause hepatotoxicity, characterized by elevated liver enzymes. Liver function tests should be performed regularly during treatment, and dose modifications may be necessary to manage hepatotoxicity.
